Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)
<b>Background</b>: Cannabidiol (CBD) is an approved treatment for childhood epilepsies and a candidate treatment for several other CNS disorders. However, it has poor oral bioavailability. We investigated the effect of a novel lipid formulation on its absorption in humans and on its tiss...
Saved in:
| Main Authors: | Edward Chesney, Ndabezinhle Mazibuko, Dominic Oliver, Amedeo Minichino, Ayşe Doğa Lamper, Lucy Chester, Thomas J. Reilly, Millie Lloyd, Matilda Kråkström, Alex M. Dickens, Matej Orešič, Eric Lynch, Gregory Stoloff, Mitul A. Mehta, Philip McGuire |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/12/1537 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Possible Anxiolytic Effects of Cannabidiol (CBD) Administration on Feline Responses to a Fear Response Test
by: Nobuo Masataka
Published: (2025-06-01) -
Cannabidiol, from Past to Present: a Review
by: Andra Popescu, Alexandra Dreanca, Orsolya Sarpataki, Mihai Cernea, Aurelia Jourdan, Ioan Marcus
Published: (2023-06-01) -
Cannabidiol (CBD) as a potential therapeutic agent for liver cancer: a comprehensive review of current evidence
by: Mojtaba Esmaeli, et al.
Published: (2025-06-01) -
Patterns of cannabidiol use among marijuana users in the United States
by: Ji-Yeun Park
Published: (2025-02-01) -
Effects of cannabidiol (CBD) treatment on age-related cognitive decline in C57 mice
by: Behroo Mirza Agha, et al.
Published: (2025-05-01)